Author:
Karimi Mohammad Amin,Ghajari Alireza,Khademi Reza,Etemadi Mohammad Hossein,Firouz Narges Safar,Mohammadvand Behnaz,Janeshin Kimia,Darvishi Afra,Asgarzadeh Shafagh,Sadat-Madani Sayedeh-Fatemeh,Abbasalizadeh Mohammad,Shendi Zahra Jafari,Kohnehshahri Ata Akhtari,Deravi Niloofar,Mazhari Seyed Amirhossein,Aziz Mahsa,Bidares Matin,Belbasi Mohaddeseh,Naziri Mahdyieh,Motlagh Hossein Ashkpour
Reference27 articles.
1. Adenosine A2A receptor availability in patients with early- and moderate-stage Parkinson’s disease - PubMed [Internet]. [cited 2024 Jun 7]. Available from: 〈https://pubmed.ncbi.nlm.nih.gov/36053386/〉.
2. An update on the management of young-onset Parkinson’s disease - PMC [Internet]. [cited 2024 Jun 7]. Available from: 〈https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065598/〉.
3. Adenosine A(2A) receptor antagonist treatment of Parkinson’s disease;Bara-Jimenez;Neurology,2003
4. Parkinson’s disease;Bloem;Lancet,2021
5. Challenges in Parkinson’s disease: restoration of the nigrostriatal dopamine system is not enough - ScienceDirect [Internet]. [cited 2024 Jun 7]. Available from: 〈https://www.sciencedirect.com/science/article/abs/pii/S1474442204007409〉.